Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

Please Try Again

Password Hint : {{passwordHint}}

Remember me

Delta 9 Cannabis Inc. T.DN

Alternate Symbol(s): DLTNF

Healthcare Cannabis

Delta 9 Cannabis Inc. is a Canada-based vertically integrated cannabis company. The Company operates through three segments: Wholesale Cannabis, Retail Cannabis and Merchandise and Devices, and Business to Business. The Company sells cannabis products through its wholesale and retail sales channels and sells its cannabis growing pods to other businesses. Its cannabis products include dried cannabis and pre-rolled joints. Its edibles and vapes include vape pens and concentrates, edibles, and drinkables. The Company, through its wholly owned subsidiary, Delta 9 Bio-Tech Inc., is a licensed producer of medical and recreational cannabis products and operates a 95,000-square-foot Health Canada licensed production facility in Winnipeg, Manitoba, Canada. It also owns and operates a chain of retail stores under the Delta 9 Cannabis Store brand. It is focused on producing and selling cannabis oils, extracts, and derivative products.

TSX:DN - Post by User

Delta 9 Cannabis Inc.

<< Previous

Bullboard Posts

Next >>

Post by gnote1on Apr 01, 2021 4:15pm

157 Views

Post# 32924959

Interview

https://ca.paidpromotionalmessages.com/companies/news/945659/delta-9-cannabis-ceo-reveals-record-142m-in-revenue-for-4q-with-plans-to-penetrate-into-the-us-945659.html

"Delta 9 Cannabis Inc (TSE:DN) (OTCQX:DLNTF) CEOJohn Arbuthnot tells Proactive the Winnipeg-based group posted strong quarterly and year-end results including a company-record 4Q revenue of $14.2 million and $52 million for the year. Arbuthnot says the quarterly figure was a 34% increase compared to the $10.6 million in the year-ago quarter, while the firm’s 2020 revenue total was up 64% from 2019 levels of $31.8 million. Arbuthnot also spoke about its focus shifting from the Canadian market, into the US."